---

NON-RESOLVING PNEUMONIA — COMPREHENSIVE A2 ANSWER

---

1. INTRODUCTION & DEFINITION

Lack of clinical improvement or worsening of symptoms despite a minimum of 10 days of appropriate antibiotic therapy, OR failure of radiographic abnormalities to clear after 2–3 months.

• S. pneumoniae (bacteremic): 18 weeks
• Legionella: up to 12 weeks
• S. aureus, gram-negative rods: up to 8–10 weeks
• Viral: 3–4 weeks
• Elderly/COPD: significantly delayed

---

2. ETIOLOGY

A. Infectious Causes (~40% of hospitalized CAP nonresponse cases)

• Streptococcus pneumoniae (DRSP – drug-resistant S. pneumoniae)
• Staphylococcus aureus (especially CA-MRSA)
• Pseudomonas aeruginosa (~10% of nonresponding CAP — not covered by standard empirical CAP therapy unless a fluoroquinolone is used)
• Legionella pneumophila
• Acinetobacter baumannii (nosocomial)
• Klebsiella pneumoniae (hypervirulent strains)
• Atypicals — Mycoplasma pneumoniae, Chlamydophila spp., Coxiella burnetii

• Mycobacterium tuberculosis, NTM (non-tuberculous mycobacteria)
• Nocardia spp.
• Endemic fungi: Histoplasma capsulatum, Coccidioides immitis, Blastomyces dermatitidis
• Opportunistic fungi: Aspergillus spp., Cryptococcus neoformans
• Pneumocystis jirovecii (PJP)
• Anaerobes (lung abscess)
• Parasites/protozoa (rare)
• Viruses (CMV, influenza, COVID-19)

• Empyema (most frequent complication — must always evaluate pleural effusion with thoracentesis)
• Lung abscess / Necrotizing pneumonia
• Metastatic infection: endocarditis, septic arthritis, pericarditis, meningitis, peritonitis
• Endobronchial obstruction (tumor, foreign body, teeth)
• Superinfection with a second organism

• Immunocompromise: HIV/AIDS, neutropenia, organ transplant, hematological malignancy
• Hypogammaglobulinemia, complement deficiencies
• Structural lung disease: bronchiectasis, COPD, cystic fibrosis

B. Noninfectious Causes (~22% of nonresponding CAP)

C. Iatrogenic/Treatment Causes

• Incorrect antibiotic choice
• Subtherapeutic dosing
• Poor compliance / bioavailability
• Inadequate duration of therapy

---

3. PATHOPHYSIOLOGY & PATHOGENESIS

Normal Pneumonia Resolution Mechanism

1. Alveolar macrophages clear debris and apoptotic neutrophils
2. Lymphocyte-mediated resolution controls inflammation
3. Epithelial repair restores alveolar architecture
4. Radiographic clearance lags clinical improvement by weeks

Mechanisms of Non-Resolution

• Organism not covered by empirical antibiotic (e.g., P. aeruginosa, TB, fungi)
• Antibiotic resistance (DRSP, MRSA, ESBL-producers)
• Biofilm formation (particularly P. aeruginosa in structural lung disease)
• High inoculum / virulence factors overwhelming host defenses
• Intracellular organisms (Legionella, Mycobacteria) with poor antibiotic penetration

• Neutrophil dysfunction (congenital or acquired)
• B-cell/humoral deficiency (poor opsonization)
• T-cell/cellular deficiency (AIDS, transplant — impairs clearance of intracellular pathogens)
• Impaired ciliary clearance (PCD, bronchiectasis)
• Anatomical obstruction preventing drainage

• Endobronchial obstruction → post-obstructive pneumonia (incomplete drainage)
• Foreign body aspiration
• Bronchiectasis — chronic bacterial colonization

• In COP/BOOP: organizing fibroblastic tissue (Masson bodies) fills alveoli and bronchioles, causing persistent consolidation unresponsive to antibiotics
• In eosinophilic pneumonia: eosinophilic infiltration persists until steroids are given
• Lymphangitic carcinomatosis/lepidic growth: mimics consolidation

• ~30% of cases show no specific cause — attributed to exaggerated or diminished inflammatory response or comorbidities

---

4. CLASSIFICATION

A. By Time Course

B. By Etiology

1. Infectious — Resistant organisms, unusual organisms, complications (empyema, abscess)
2. Noninfectious — Neoplasm, vascular, organizing, eosinophilic, drug-induced, vasculitis
3. Unknown etiology — ~30% of cases despite adequate workup

C. By Immunologic Status

1. Immunocompetent host
2. Immunocompromised host (transplant, HIV, chemotherapy, biological agents)
3. Structurally abnormal lung (COPD, bronchiectasis, CF)

D. Kuru & Lynch Classification (Clin Chest Med, 1999 — referenced in Fishman)

• Type 1: Slow resolution (clinically improving, delayed x-ray clearance)
• Type 2: True non-resolution (no clinical or radiographic improvement)
• Type 3: Relapse after initial improvement

---

5. CLINICAL FEATURES

Symptoms

• Persistent fever beyond 72–96 hours of antibiotic therapy
• Ongoing productive cough (purulent/bloody sputum)
• Chest pain (pleuritic — suggests empyema or PE)
• Dyspnea (progressive — suggests deteriorating pattern)
• Hemoptysis (suggests carcinoma, TB, necrotizing pneumonia, vasculitis)
• Weight loss, night sweats (suggests TB, malignancy)
• Extrapulmonary symptoms:
  • Joint pain, skin lesions → vasculitis, sarcoidosis
  • Peripheral neuropathy → sarcoidosis
  • Urinary symptoms → Legionella
  • Diarrhea, confusion → Legionella, atypical CAP

Physical Examination

• Persistent dullness to percussion (consolidation, pleural effusion)
• Decreased air entry (effusion, obstruction)
• Bronchial breath sounds
• Clubbing (suggests chronic infection, malignancy, fibrosis)
• Lymphadenopathy (TB, lymphoma, sarcoidosis)
• Signs of specific etiology:
  • Skin rash → drug reaction, vasculitis
  • Renal impairment → Goodpasture, GPA
  • Hepatomegaly → lymphoma, fungal infection

Laboratory Red Flags

• Persistently elevated PCT / CRP despite treatment (independent predictor of nonresponse)
• Elevated IL-6 at presentation → predicts inadequate response
• Eosinophilia → eosinophilic pneumonia, ABPA, parasites
• Lymphopenia → HIV, transplant
• High LDH → PJP, malignancy
• Elevated ANA, ANCA, anti-GBM → vasculitis

---

6. DIAGNOSIS

Step 1: Re-evaluation at 72 Hours

• Full history: travel, animal/occupational/environmental exposures, personal habits, medications, epidemiology
• Physical examination
• Biomarkers: PCT, CRP, IL-6

Step 2: Microbiological Studies (Intensified)

Step 3: Imaging

• Assess for progression, new infiltrates, cavitation, pleural effusion, mediastinal widening

Step 4: Bronchoscopy

• BAL for: culture (bacteria, TB, fungi, viral PCR), cytology, differential cell count, galactomannan
• Bronchial washings for mycobacteria
• TBLB (transbronchial lung biopsy): organizing pneumonia, sarcoidosis, malignancy
• Endobronchial biopsy: carcinoma, carcinoid, granulomatous lesions
• Identify endobronchial obstruction: tumor, foreign body, mucus plugging
• Protected specimen brush (PSB): quantitative cultures for VAP/HAP

Step 5: Surgical/Invasive Diagnosis (Selected Cases)

• CT-guided percutaneous biopsy: peripheral lesions, suspected malignancy
• VATS/Surgical lung biopsy: when transbronchial biopsy insufficient (UIP, NSIP, COP confirmation)
• EBUS-TBNA: mediastinal lymphadenopathy (lymphoma, sarcoidosis, malignancy)
• Thoracentesis + pleural biopsy: exudative effusion (empyema, mesothelioma, TB)

---

7. HRCT FINDINGS IN NON-RESOLVING PNEUMONIA

A. Infectious Patterns

B. Noninfectious Mimics — HRCT Patterns

C. Specific HRCT Clues for Diagnosis in NRP

---

8. TREATMENT

A. General Approach

1. Evaluate at 72 hours after antibiotic initiation
2. Broaden spectrum if clinical deterioration
3. Narrow therapy once causative organism identified
4. Treat the underlying noninfectious cause if identified
5. Drain all parapneumonic effusions meeting criteria
6. Correct host abnormalities: immunodeficiency, glycemic control, reduce immunosuppressants if safe

B. Antibiotic Therapy — Modified for Non-Resolving CAP

Empirical Broadening Strategy

• Vancomycin 15–20 mg/kg IV q8–12h (target AUC/MIC 400–600)
• OR Linezolid 600 mg IV/PO q12h (superior lung penetration, some guidelines prefer for pneumonia)

• Piperacillin-tazobactam 4.5 g IV q6h (extended infusion preferred: over 4 hours)
• OR Cefepime 2 g IV q8h
• OR Meropenem 1–2 g IV q8h (ESBL-suspected)
• OR Imipenem-cilastatin 500 mg IV q6h

• Ciprofloxacin 400 mg IV q8h (or 500–750 mg PO q12h)

Specific Pathogen-Directed Therapy

Newer/Novel Therapies (Post-2018)

C. Treatment of Noninfectious Causes

D. Role of Adjunctive Corticosteroids in Severe CAP

• Corticosteroids in severe CAP: associated with reduced need for mechanical ventilation and shorter ICU stay
• Dexamethasone 6 mg IV q24h × 4 days (or Methylprednisolone 0.5 mg/kg q12h) in ICU patients with severe CAP
• NOT recommended for mild-moderate CAP

---

9. ERS GUIDELINES SUMMARY (2019–2023)

ERS/ESCMID Guidelines for Nonresponding CAP (Torres A et al., Eur Respir J 2013; updated in ERS 2019 CAP Guidelines)

1. Define treatment failure: Clinical deterioration or no improvement after 72 hours; radiographic non-resolution after 2–3 months
2. PCT monitoring: Reduction by day 3–4 predicts adequate response; failure to fall → evaluate for nonresponse
3. CT chest: Recommended for all patients with suspected treatment failure (Grade B)
4. Bronchoscopy: Recommended when CT fails to establish diagnosis and in immunocompromised patients (Grade B)
5. Empirical coverage adjustment:
   • Add MRSA coverage (vancomycin or linezolid) if risk factors present
   • Add Pseudomonas coverage (β-lactam with antipseudomonal activity) if risk factors present
   • Broaden fungal coverage if immunocompromised
6. Severity assessment at 72 hours using clinical + biomarker response
7. Steroids: Consider dexamethasone in ICU patients with severe refractory CAP
8. Antibiotic stewardship: De-escalate promptly when culture data available
9. Drainage of empyema: Early drainage mandatory; intrapleural fibrinolytics (MIST2 trial: tPA + DNase) if septated
10. Chest CT findings guide biopsy approach — CT-guided, bronchoscopic, or surgical

ERS/ATS Minimum Standards for Non-Resolving Pneumonia Workup:

• Repeat blood cultures (2 sets)
• Legionella urinary antigen
• Pneumococcal urinary antigen
• BAL via bronchoscopy
• Chest CT
• Consider thoracentesis for any pleural effusion

---

10. DIAGNOSTIC ALGORITHM (Summary)

NON-RESOLVING PNEUMONIA
        │
        ▼
CLINICAL REASSESSMENT at 72h
(History, Exam, PCT/CRP/IL-6)
        │
    ┌───┴────────────────────┐
DETERIORATING              NON-RESPONDING
    │                           │
Broaden antibiotics         Chest CT
(add MRSA + Pseudo)             │
Consider ICU                ┌───┴────────────────────┐
                     INFECTIOUS CAUSE          NONINFECTIOUS CAUSE
                     SUSPECTED                 SUSPECTED
                            │                       │
                      Bronchoscopy +           Biopsy (CT-guided
                      Cultures + BAL           or bronchoscopic or
                      Serology                 surgical)
                      Galactomannan                  │
                            │                  COP → Steroids
                    Specific directed          Eosinophilic → Steroids
                    therapy                    Sarcoidosis → Steroids
                                              Vasculitis → IS
                                              Malignancy → Oncology

---

KEY POINTS SUMMARY

---

• Fishman's Pulmonary Diseases and Disorders, 5th Ed. — Chapter 33 (Bronchoscopy & Pulmonary Infections)
• Murray & Nadel's Textbook of Respiratory Medicine, 7th Ed. — Chapter 46 (Community-Acquired Pneumonia: Nonresponding Pneumonia/Treatment Failure, Table 46.6)
• ERS/ATS/IDSA CAP Guidelines 2019–2021
• Saleem N et al. "Effect of Corticosteroids on Mortality and Clinical Cure in CAP." Chest 2023. [PMID 36087797]
• Kuru T, Lynch JP 3rd. "Nonresolving or slowly resolving pneumonia." Clin Chest Med. 1999;20:623–651 (referenced in Fishman)This is your full A2-style detailed answer on Non-Resolving Pneumonia, synthesized primarily from Fishman's Pulmonary Diseases and Disorders and Murray & Nadel's Textbook of Respiratory Medicine, cross-referenced with ERS guidelines and current PubMed evidence. Here is a structured summary of what was covered:

---

What Was Covered

1. Introduction & Definition

2. Etiology

• Infectious (~40%): Resistant organisms (DRSP, MRSA, MDR P. aeruginosa), unusual pathogens (TB, NTM, fungi, PJP, Nocardia), and infectious complications (empyema, abscess, metastatic infection)
• Noninfectious (~22%): COP/BOOP, eosinophilic pneumonia, organizing diseases, vasculitis (GPA, MPA), pulmonary infarction, drug-induced, malignancy (lepidic adenocarcinoma is a classic mimic)
• Unknown (~30%): No specific cause despite full workup

3. Pathophysiology & Pathogenesis

4. Classification

5. Clinical Features

6. Diagnosis

7. HRCT Findings (Extensive)

• Infectious: tree-in-bud (TB/NTM), halo sign (aspergillosis), cavitation (abscess/TB), necrotizing pneumonia, miliary
• Noninfectious mimics: reverse halo/atoll sign (COP), peripheral upper-lobe consolidation (CEP), perilymphatic nodules (sarcoidosis), CT angiogram sign (BAC/lepidic adenocarcinoma), Hampton's hump (PE)

8. Treatment

• Empirical broadening strategies (add MRSA + Pseudomonas coverage)
• Organism-directed therapy with drugs and doses for all major pathogens
• Newer antibiotics: Ceftazidime-avibactam, Ceftolozane-tazobactam, Cefiderocol, Meropenem-vaborbactam, Imipenem-relebactam, Omadacycline, Lefamulin, Isavuconazole, Baloxavir
• Noninfectious treatment: steroids for COP/eosinophilic pneumonia/HP/drug-induced, immunosuppressants for vasculitis, intrapleural tPA+DNase for empyema
• Adjunctive dexamethasone for severe ICU CAP (per ERS 2021 + Chest 2023 meta-analysis)

9. ERS Guidelines